The most common adverse events were hyperglycaemia ( @ -LSB- @ % -RSB- for treatment with @ mg pasireotide , @ -LSB- @ % -RSB- with @ mg pasireotide , and nine -LSB- @ % -RSB- with active control ) , diabetes ( @ -LSB- @ % -RSB- , @ -LSB- @ % -RSB- , and five -LSB- @ % -RSB- ) , and diarrhoea ( ten -LSB- @ % -RSB- , @ -LSB- @ % -RSB- , and three -LSB- @ % -RSB- ) ; most were grade @ or @ in severity .